Osama A A Ahmed1,2, Usama A Fahmy1, Rana Bakhaidar1, Mohamed A El-Moselhy3,4, Mohamed A Alfaleh5, Al-Shaimaa F Ahmed4, Asmaa S A Hammad4, Hibah Aldawsari1, Nabil A Alhakamy1,6,7,8. 1. Advanced Drug Delivery Research Group, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia. 2. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Minia University, Minia 61519, Egypt. 3. Department of Pharmacology, School of Pharmacy, Ibn Sina National College, Jeddah 22413, Saudi Arabia. 4. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, Minia 61519, Egypt. 5. Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. 6. Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia. 7. Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia. 8. King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Abstract
BACKGROUND: Peptic ulcer disease, a painful lesion of the gastric mucosa, is considered one of the most common gastrointestinal disorders. This study aims to investigate the formulation of pumpkin seed oil (PSO)-based nanostructured lipid carriers (NLCs) to utilize PSO as the liquid lipid component of NLCs and to achieve oil dispersion in the nano-range in the stomach. METHODS: Box-Behnken design was utilized to deduce the optimum formula with minimum particle size. The optimized PSO-NLCs formula was investigated for gastric ulcer protective effects in Wistar rats by evaluating ulcer index and determination of gastric mucosa oxidative stress parameters. RESULTS: PSO was successfully incorporated as the liquid lipid (LL) component of NLCs. The prepared optimum PSO-NLCs formula showed a size of 64.3 nm. Pretreatment of animals using the optimized PSO-NLCs formula showed significantly (p< 0.001) lower ulcer index compared to indomethacin alone group and significantly (p<0.05) less mucosal lesions compared to the raw oil. CONCLUSION: These results indicated great potential for future application of optimized PSO-NLCs formula for antiulcer effect in non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer.
BACKGROUND: Peptic ulcer disease, a painful lesion of the gastric mucosa, is considered one of the most common gastrointestinal disorders. This study aims to investigate the formulation of pumpkin seed oil (PSO)-based nanostructured lipid carriers (NLCs) to utilize PSO as the liquid lipid component of NLCs and to achieve oil dispersion in the nano-range in the stomach. METHODS: Box-Behnken design was utilized to deduce the optimum formula with minimum particle size. The optimized PSO-NLCs formula was investigated for gastric ulcer protective effects in Wistar rats by evaluating ulcer index and determination of gastric mucosa oxidative stress parameters. RESULTS: PSO was successfully incorporated as the liquid lipid (LL) component of NLCs. The prepared optimum PSO-NLCs formula showed a size of 64.3 nm. Pretreatment of animals using the optimized PSO-NLCs formula showed significantly (p< 0.001) lower ulcer index compared to indomethacin alone group and significantly (p<0.05) less mucosal lesions compared to the raw oil. CONCLUSION: These results indicated great potential for future application of optimized PSO-NLCs formula for antiulcer effect in non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer.
Authors: Benjamin Scally; Jonathan R Emberson; Enti Spata; Christina Reith; Kelly Davies; Heather Halls; Lisa Holland; Kate Wilson; Neeraj Bhala; Christopher Hawkey; Marc Hochberg; Richard Hunt; Loren Laine; Angel Lanas; Carlo Patrono; Colin Baigent Journal: Lancet Gastroenterol Hepatol Date: 2018-02-21
Authors: Shaimaa M Badr-Eldin; Usama A Fahmy; Hibah M Aldawsari; Osama A A Ahmed; Nabil A Alhakamy; Solomon Z Okbazghi; Mohamed A El-Moselhy; Adel F Alghaith; Aliaa Anter; Asmaa I Matouk; Wael Ali Mahdi; Sultan Alshehri; Rana Bakhaidar Journal: Dose Response Date: 2021-03-30 Impact factor: 2.658